These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

327 related articles for article (PubMed ID: 23846010)

  • 1. B-type natriuretic peptide. Guided vs. conventional care in outpatients with chronic heart failure: a retrospective study.
    De Vecchis R; Esposito C; Di Biase G; Ariano C
    Minerva Cardioangiol; 2013 Aug; 61(4):437-49. PubMed ID: 23846010
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of adding nitroglycerin to early diuretic therapy on the morbidity and mortality of patients with chronic kidney disease presenting with acute decompensated heart failure.
    Aziz EF; Kukin M; Javed F; Pratap B; Sabharwal MS; Tormey D; Frankenberger O; Herzog E
    Hosp Pract (1995); 2011 Feb; 39(1):126-32. PubMed ID: 21441767
    [TBL] [Abstract][Full Text] [Related]  

  • 3. BNP-guided vs symptom-guided heart failure therapy: the Trial of Intensified vs Standard Medical Therapy in Elderly Patients With Congestive Heart Failure (TIME-CHF) randomized trial.
    Pfisterer M; Buser P; Rickli H; Gutmann M; Erne P; Rickenbacher P; Vuillomenet A; Jeker U; Dubach P; Beer H; Yoon SI; Suter T; Osterhues HH; Schieber MM; Hilti P; Schindler R; Brunner-La Rocca HP;
    JAMA; 2009 Jan; 301(4):383-92. PubMed ID: 19176440
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Plasma renin activity is a strong and independent prognostic indicator in patients with acute decompensated heart failure treated with renin-angiotensin system inhibitors.
    Ueda T; Kawakami R; Nishida T; Onoue K; Soeda T; Okayama S; Takeda Y; Watanabe M; Kawata H; Uemura S; Saito Y
    Circ J; 2015; 79(6):1307-14. PubMed ID: 25753468
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Microvascular tissue perfusion is impaired in acutely decompensated heart failure and improves following standard treatment.
    Lauten A; Ferrari M; Goebel B; Rademacher W; Schumm J; Uth O; Kiehntopf M; Figulla HR; Jung C
    Eur J Heart Fail; 2011 Jul; 13(7):711-7. PubMed ID: 21543374
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and tolerability of intensified, N-terminal pro brain natriuretic peptide-guided compared with standard medical therapy in elderly patients with congestive heart failure: results from TIME-CHF.
    Sanders-van Wijk S; Muzzarelli S; Neuhaus M; Kiencke S; Maeder M; Estlinbaum W; Tobler D; Mayer K; Erne P; Pfisterer ME; Brunner-La Rocca HP;
    Eur J Heart Fail; 2013 Aug; 15(8):910-8. PubMed ID: 23666681
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Brain natriuretic peptide-guided treatment does not improve morbidity and mortality in extensively treated patients with chronic heart failure: responders to treatment have a significantly better outcome.
    Karlström P; Alehagen U; Boman K; Dahlström U;
    Eur J Heart Fail; 2011 Oct; 13(10):1096-103. PubMed ID: 21715446
    [TBL] [Abstract][Full Text] [Related]  

  • 8. N-terminal pro-B-type natriuretic peptide-guided treatment for chronic heart failure: results from the BATTLESCARRED (NT-proBNP-Assisted Treatment To Lessen Serial Cardiac Readmissions and Death) trial.
    Lainchbury JG; Troughton RW; Strangman KM; Frampton CM; Pilbrow A; Yandle TG; Hamid AK; Nicholls MG; Richards AM
    J Am Coll Cardiol; 2009 Dec; 55(1):53-60. PubMed ID: 20117364
    [TBL] [Abstract][Full Text] [Related]  

  • 9. B-type natriuretic Peptide-guided treatment for predicting outcome in patients hospitalized in sub-intensive care unit with acute heart failure.
    Valle R; Aspromonte N; Giovinazzo P; Carbonieri E; Chiatto M; di Tano G; Feola M; Milli M; Fontebasso A; Barro S; Bardellotto S; Milani L
    J Card Fail; 2008 Apr; 14(3):219-24. PubMed ID: 18381185
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Plasma brain natriuretic peptide-guided therapy to improve outcome in heart failure: the STARS-BNP Multicenter Study.
    Jourdain P; Jondeau G; Funck F; Gueffet P; Le Helloco A; Donal E; Aupetit JF; Aumont MC; Galinier M; Eicher JC; Cohen-Solal A; Juillière Y
    J Am Coll Cardiol; 2007 Apr; 49(16):1733-9. PubMed ID: 17448376
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Importance of Worsening Heart Failure in Ambulatory Patients: Definition, Characteristics, and Effects of Amino-Terminal Pro-B-Type Natriuretic Peptide Guided Therapy.
    Mallick A; Gandhi PU; Gaggin HK; Ibrahim N; Januzzi JL
    JACC Heart Fail; 2016 Sep; 4(9):749-55. PubMed ID: 27179830
    [TBL] [Abstract][Full Text] [Related]  

  • 12. N-terminal pro-B-type natriuretic peptide-guided, intensive patient management in addition to multidisciplinary care in chronic heart failure a 3-arm, prospective, randomized pilot study.
    Berger R; Moertl D; Peter S; Ahmadi R; Huelsmann M; Yamuti S; Wagner B; Pacher R
    J Am Coll Cardiol; 2010 Feb; 55(7):645-53. PubMed ID: 20170790
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic utility of B-type natriuretic peptide assessment in stable low-risk outpatients with nonischemic cardiomyopathy after decompensated heart failure.
    Nishii M; Inomata T; Takehana H; Naruke T; Yanagisawa T; Moriguchi M; Takeda S; Izumi T
    J Am Coll Cardiol; 2008 Jun; 51(24):2329-35. PubMed ID: 18549918
    [TBL] [Abstract][Full Text] [Related]  

  • 14. B-type natriuretic peptide-guided heart failure therapy: A meta-analysis.
    Porapakkham P; Porapakkham P; Zimmet H; Billah B; Krum H
    Arch Intern Med; 2010 Mar; 170(6):507-14. PubMed ID: 20308637
    [TBL] [Abstract][Full Text] [Related]  

  • 15. B-type natriuretic peptide-guided versus symptom-guided therapy in outpatients with chronic heart failure: a systematic review with meta-analysis.
    De Vecchis R; Esposito C; Di Biase G; Ariano C; Giasi A; Cioppa C
    J Cardiovasc Med (Hagerstown); 2014 Feb; 15(2):122-34. PubMed ID: 24522083
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of the prognostic usefulness of N-terminal pro-brain natriuretic Peptide in patients with heart failure with versus without chronic kidney disease.
    Bruch C; Fischer C; Sindermann J; Stypmann J; Breithardt G; Gradaus R
    Am J Cardiol; 2008 Aug; 102(4):469-74. PubMed ID: 18678308
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Plasma B-type natriuretic peptide reduction predicts long-term response to levosimendan therapy in acutely decompensated chronic heart failure.
    Farmakis D; Parissis JT; Bistola V; Paraskevaidis IA; Iliodromitis EK; Filippatos G; Kremastinos DT
    Int J Cardiol; 2010 Feb; 139(1):75-9. PubMed ID: 18973957
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lowered B-type natriuretic peptide in response to levosimendan or dobutamine treatment is associated with improved survival in patients with severe acutely decompensated heart failure.
    Cohen-Solal A; Logeart D; Huang B; Cai D; Nieminen MS; Mebazaa A
    J Am Coll Cardiol; 2009 Jun; 53(25):2343-8. PubMed ID: 19539144
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effectiveness of serial increases in amino-terminal pro-B-type natriuretic peptide levels to indicate the need for mechanical circulatory support in children with acute decompensated heart failure.
    Wong DT; George K; Wilson J; Manlhiot C; McCrindle BW; Adeli K; Kantor PF
    Am J Cardiol; 2011 Feb; 107(4):573-8. PubMed ID: 21295174
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Plasma brain natriuretic peptide predicts short-term clinical outcome in heart failure patients with restrictive filling pattern.
    Feola M; Aspromonte N; Milani L; Bobbio M; Bardellotto S; Barro S; Giovinazzo P; Noventa F; Valle R
    J Card Fail; 2008 Jun; 14(5):420-5. PubMed ID: 18514935
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.